Literature DB >> 16877988

Hyaluronic acid predicts hepatic fibrosis in children with hepatic disease.

Jane L Hartley1, Rachel M Brown, Aniela Tybulewicz, Peter Hayes, David C Wilson, Peter Gillett, Patrick McKiernan.   

Abstract

BACKGROUND: Hyaluronic acid (HA) is removed by the liver via sinusoidal cell adhesion molecules. This is impeded in fibrosis, leading to a rise in serum HA. As a noninvasive marker of fibrosis, HA may obviate the need for liver biopsy.
OBJECTIVE: To evaluate HA as a marker of hepatic fibrosis, in unselected children undergoing liver biopsy.
METHODS: Ninety-three unselected consecutive children (median age, 7.5 years; range, 0.07-19 years) undergoing a liver biopsy between April 2003 and March 2004 were prospectively recruited. Liver biopsy and fasting HA levels were taken simultaneously. The Ishak score was used to stage fibrosis. Scores of 3 or greater were regarded as significant fibrosis. Hyaluronic acid levels were measured using an enzyme-linked binding protein assay (2002 Corgenix, Inc) (adult reference range, 0-75 ng/mL; pediatric reference range, 0-30 ng/mL).
RESULTS: Twenty-three (25%) of 93 biopsies had significant fibrosis, and HA levels in this group were significantly higher than those with mild fibrosis (Ishak score, <3), (median level, 72 ng/mL vs 30 ng/mL; Mann-Whitney U test; P < 0.005). Hyaluronic acid level of 50 ng/mL had a positive predictive value 40% and negative predictive value 86% for significant fibrosis. An HA level 200 ng/mL has a sensitivity of 26% and specificity of 90%.
CONCLUSIONS: Hyaluronic Acid is a valid noninvasive predictor of hepatic fibrosis in unselected children with liver disease. An HA level of 200 ng/mL strongly suggests significant fibrosis. Hyaluronic acid level of less than 50 ng/mL accurately identifies those who do not have significant fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877988     DOI: 10.1097/01.mpg.0000228121.44606.9f

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  9 in total

1.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

Review 2.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

4.  Serum hyaluronic acid concentration in Fontan circulation: correlation with hepatic function and portal vein hemodynamics.

Authors:  Taiyu Hayashi; Ryo Inuzuka; Takahiro Shindo; Yoichiro Hirata; Nobutaka Shimizu; Akira Oka
Journal:  Pediatr Cardiol       Date:  2013-10-26       Impact factor: 1.655

5.  The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.

Authors:  Pamela Valva; Paola Casciato; Juan M Diaz Carrasco; Adrian Gadano; Omar Galdame; María Cristina Galoppo; Eduardo Mullen; Elena De Matteo; María Victoria Preciado
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

6.  Determination of the relationship of serum hyaluronic Acid levels to the degree of liver fibrosis in biopsies of patients with chronic viral hepatitis B and C.

Authors:  Faride Moradi Moghaddam; Hossein Arrbabi; Mohammad Khajedaloei
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

Review 7.  Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis.

Authors:  Sahar Rostami; Hadi Parsian
Journal:  Hepat Mon       Date:  2013-12-14       Impact factor: 0.660

8.  Serum hyaluronic acid concentration predicts the progression of joint space narrowing in normal knees and established knee osteoarthritis - a five-year prospective cohort study.

Authors:  Eiji Sasaki; Eiichi Tsuda; Yuji Yamamoto; Shugo Maeda; Ryo Inoue; Daisuke Chiba; Hiroshi Fujita; Ippei Takahashi; Takashi Umeda; Shigeyuki Nakaji; Yasuyuki Ishibashi
Journal:  Arthritis Res Ther       Date:  2015-10-10       Impact factor: 5.156

9.  Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp.

Authors:  Laura M Keller; Stephanie Eighmy; Cun Li; Lauryn Winter; Jay Kerecman; Zachary Goodman; Naveen Mittal; Cynthia L Blanco
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.